Showing 39,381 - 39,400 results of 102,147 for search '(( 2 step decrease ) OR ( 5 ((point decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.74s Refine Results
  1. 39381
  2. 39382

    The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology by Mohsen Sadatsafavi (63962)

    Published 2018
    “…<div><p>Background</p><p>There is minimal evidence on the extent to which the occurrence of a severe acute exacerbation of COPD that results in hospitalization affects the subsequent disease course. …”
  3. 39383
  4. 39384
  5. 39385

    Core–Shell {Mn<sub>7</sub>⊂(Mn,Cd)<sub>12</sub>} Assembled from Core {Mn<sub>7</sub>} Disc by Ling-Yu Guo (3068232)

    Published 2017
    “…HR-ESI-MS was even more precise by revealing three prominent molecular species, Mn<sub>13</sub>Cd<sub>6</sub>, Mn<sub>14</sub>Cd<sub>5</sub> and Mn<sub>15</sub>Cd<sub>4</sub>, having a distribution of metals. …”
  6. 39386

    Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week... by Takashi Kadowaki (35402)

    Published 2017
    “…</p> <p><b>Research design and methods</b>: We randomized 240 patients with type 2 diabetes mellitus on insulin monotherapy to 5-mg saxagliptin or placebo as add-on therapy for a 16-week, double-blind period. …”
  7. 39387
  8. 39388

    RPIA regulates colon cell proliferation through β-catenin expression in HCT116 cells. by Yu-Ting Chou (447778)

    Published 2018
    “…<i>AXIN2</i>, <i>Axis inhibition protein 2</i>; <i>CCND1</i>, <i>Cyclin D1</i>; <i>CCNE2</i>, <i>Cyclin E2</i>; <i>CTNNB1</i>, <i>CATENIN BETA 1</i>; pcDNA, pcDNA3 vector control; qPCR, quantitative PCR; RPIA, ribose-5-phosphate isomerase A; si-NC, negative control small interfering RNA; si-RPIA, RPIA small interfering RNA; TCF, T-cell transcription factor.…”
  9. 39389

    An idealized view of the opportunity provided by a comparative and integrated oncology drug development path. by Ira Gordon (369869)

    Published 2013
    “…Factoring in additional costs for comparative studies with this approach of US$150,000 for studies conducted in the preclinical setting, US$250,000 for studies conducted before or during Phases I–II human trials and US$1 million for studies conducted before Phases II–III studies, the total cost of development is estimated at US$2.07 billion. The result may be a decrease in average clinical trial costs per approved drug from US$290 million to US$173 million <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000161#pmed.1000161-Adams1" target="_blank">[5]</a>.…”
  10. 39390
  11. 39391

    Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study by Jennifer E. Nyland (11412878)

    Published 2021
    “…Use of DPP-4 inhibitors was associated with a reduction in respiratory complications (24.0% vs 29.2%; RR, 0.82 [95% CI, 0.74-0.90]; <i>P</i> <.001), and continued use of DPP-4 inhibitors after hospitalization was associated with a decrease in mortality compared with those who discontinued use (9% vs 19%; RR, 0.45 [95% CI, 0.28-0.72]; <i>P</i> <.001). …”
  12. 39392

    Data_Sheet_1_Expression of vitamin D receptor, CYP24A1, and CYP27B1 in normal and inflamed canine pancreases.DOCX by Dohee Lee (432106)

    Published 2023
    “…This study showed that VDR expression decreased in inflamed pancreases and demonstrated CYP24A1 and CYP27B1 expression in the canine pancreas for the first time. …”
  13. 39393
  14. 39394
  15. 39395
  16. 39396
  17. 39397
  18. 39398
  19. 39399

    An HIV-1 Envelope Immunogen with W427S Mutation in CD4 Binding Site Induced More T Follicular Helper Memory Cells and Reduced Non-Specific Antibody Responses by Hao-Tong Yu (697936)

    Published 2014
    “…We constructed a gp120 mutant W427S of an HIV-1 primary R5 strain and examined its ability in the elicitation of Ab and the production of Tfh by immunization of BALB/c mice. …”
  20. 39400

    Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population by Al AdAwi R.M.

    Published 2019
    “…Administration of dapagliflozin as an add-on therapy was found to decrease HbA1c significantly by 0.8 percentage point after 6 months (P = 0.006) and by 1.5 percentage point after 12 months (P = 0.062). …”
    Get full text
    Get full text